Last reviewed · How we verify
NCT07253948
Distribution Characteristics of Helicobacter Pylori
trial testing immunohistochemical testing in Helicobacter Pylori in 231 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Jilin University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 231 |
| Start date | 22 October 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- immunohistochemical testing
Conditions studied
- Helicobacter Pylori — all drugs for Helicobacter Pylori →
- Early Gastric Cancer — all drugs for Early Gastric Cancer →
Sponsor
Jilin University
Who can join
Adults 18 to 80, any sex, with Helicobacter Pylori or Early Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to analyze the distribution characteristics of Helicobacter pylori（H. pylori） in varying stages of atrophic gastritis and early gastric cancer using immunohistochemical staining, with the goal of providing guidance for the early screening of gastric cancer. A retrospective analysis was conducted on gastric biopsy cases that underwent H. pylori immunohistochemical staining at our center from March 1, 2023, to August 15, 2025. Cases were classified into non-atrophic and atrophic groups based on the presence or absence of gastric atrophy. All cases were further divided into non-open and open atrophy groups and additionally into early gastric cancer and non-cancer groups. The distribution of H. pylori across subgroups was compared, and multivariate analyses were performed to identify risk factors associated with the development of early gastric cancer.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07253948
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Helicobacter Pylori
Currently open trials in the same condition.
- NCT07232095 — 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy · Phase 4 · recruiting
- NCT06943781 — Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detection · recruiting
- NCT06871579 — Study of the Esophageal String Test (EST) for the Diagnosis of Helicobacter Pylori · NA · recruiting
- NCT07122024 — Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment · Phase 4 · recruiting
- NCT05053945 — Helicobacter Pylori, Atrophic Gastritis and Intestinal Metaplasia Registry and Prospective Study · recruiting
Other Jilin University trials
Trials by the same sponsor.
- NCT06454461 — Efficacy of Upadacitinib After NECS in Vitiligo · NA · recruiting
- NCT06397066 — White Light Endoscopy and Magnifying Endoscopy in Assessing the Status of Hp Infection · recruiting
- NCT06079554 — Microbiota and Metabolomics of Intestinal Type of Gastric Cancer · recruiting
- NCT06076369 — Differentiation of Tubular Adenoma and Colonic Innominate Groove Under EC Endoscopy · recruiting
- NCT06076382 — Endoscopic Ultrasound Guided Colorectal ESD and Traditional Colorectal ESD Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07253948 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jilin University
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07253948.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing